PHS
BBIO icon

PFM Health Sciences’s BridgeBio Pharma BBIO Stock Holding History

PFM Health Sciences’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9M Sell
253,358
-4,389
-2% -$307K 1.62% 16
2026
Q1 		$19.1M Sell
257,747
-48,759
-16% -$3.53M 1.75% 16
2025
Q4 		$23.4M Sell
306,506
-20,668
-6% -$1.36M 2.34% 8
2025
Q3 		$17M Sell
327,174
-194,619
-37% -$9.49M 1.31% 24
2025
Q2 		$22.5M Sell
521,793
-386,342
-43% -$14.1M 1.92% 18
2025
Q1 		$31.4M Buy
908,135
+617,893
+213% +$20.8M 2.28% 13
2024
Q4 		$7.96M Buy
+290,242
New +$7.5M 0.49% 48

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

PFM Health Sciences's BBIO Position: Q2 2026 in Review

PFM Health Sciences reduced its BridgeBio Pharma (BBIO) stake by 1.7% in Q2 2026, selling an estimated $307K and leaving 253,358 shares worth $18.9M. The position accounts for 1.62% of the portfolio, ranked #16.

PFM Health Sciences first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $31.4M in Q1 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • PFM Health Sciences held 253,358 shares of BridgeBio Pharma worth $18.9M as of Q2 2026.
  • PFM Health Sciences sold 4,389 BridgeBio Pharma shares in Q2 2026, an estimated $307K.
  • BridgeBio Pharma made up 1.62% of PFM Health Sciences's portfolio in Q2 2026, its #16 holding.
  • PFM Health Sciences first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
  • PFM Health Sciences's BridgeBio Pharma position peaked at $31.4M in Q1 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.